title: Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes. 5 year follow-up.
abstract: OBJECTIVE
  Thirty percent of patients with localized prostate cancer undergoing radical prostatectomy experience biochemical recurrence with rising serum prostate-specific antigen (PSA). More than 50% of these develop distant metastases.
  
  
  METHODS
  Presence of PSA mRNA in pathologically normal pelvic lymph nodes from 154 patients undergoing radical prostatectomy was investigated with non-quantitative PSA reverse transcriptase polymerase chain reaction (RT-PCR). In 135 of these patients preoperative serum PSA RT-PCR was also assessed. RT-PCR positivity was correlated with biochemical recurrence and compared with other clinical risk factors.
  
  
  RESULTS
  At a median follow-up of 58 months the biochemical failure-free survival of patients with positive versus negative lymph node RT-PCR was 68.4% and 76.7% respectively (p=0.2). Biochemical failure-free survival was not influenced by the serum PSA RT-PCR result either (72.3% versus 72.6%). Surgical margin status, preoperative serum PSA, pT category and Gleason score were independent prognostic risk factors for biochemical recurrence with a hazard ratio of 5.48, 2.56, 2.56 and 2.13 respectively.
  
  
  CONCLUSIONS
  At 5 year follow-up after radical prostatectomy, both serum and lymph node RT-PCR are not correlated with biochemical failure-free survival. Established clinical risk factors have a much stronger impact on biochemical recurrence.
authors.affiliation: Urology Service, La Paz University Hospital, Autonomous University of Madrid, Spain. luis@martinez-pineiro.com
authors.forename: Luis
authors.initials: L
authors.lastname: Martínez-Piñeiro
authors.forename: Montserrat
authors.initials: M
authors.lastname: Martínez-Gomariz
authors.forename: Emilio
authors.initials: E
authors.lastname: Rios
authors.forename: María L
authors.initials: ML
authors.lastname: Picazo
authors.forename: Hugo R
authors.initials: HR
authors.lastname: Arriaga
authors.forename: Rosario
authors.initials: R
authors.lastname: Perona
mesh_terms: D005500:Follow-Up Studies; D006801:Humans; D008198:Lymph Nodes / Q000737:chemistry*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000032:analysis*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors
chemical_list: D017430:Prostate-Specific Antigen